

**MO HEALTHNET DRUG UTILIZATION REVIEW BOARD**

**April 18, 2018**

**Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City MO**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Charlene Heyde, RPh  
Sandra Bollinger, Pharm D  
Randy Beckner  
Stacy Mangum, Pharm D  
Ginger Nicol, MD, CEDS  
Glen Talboy, MD  
Jennifer Passanise, FNP

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Angela Wilson, Manager, Band I  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Jenna McTeer, RN, Clinical Management  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager  
Elizabeth Short, Program Development Specialist  
Dr. Timothy Kling, MD, Assistant Medical Director

**DUR BOARD MEMBERS ABSENT**

Kenneth Haller, MD

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Richard Pope, Pharm D, Magellan

**OTHERS IN ATTENDANCE**

Mike Lafond, AbbVie  
Ashley Polce, AbbVie  
Evan Rushing, Alkermes  
Tom Guyer, Eli Lilly  
Donna Osterlund, Genzyme  
Berend Koops, Merck  
Marla Wiedermann, Novo Nordisk  
Nick Wagner, Pfizer  
Mike Holmes, Sunovion

Jennifer Wilbanks, Sunovion  
Kristin Homoly, Synergy  
Robert Pearce, Teva  
Shelialie Patel, Wipro  
Geri Roling, Wipro

<b>Welcome, Introductions and Opening Remarks</b>	Susan Abdel-Rahman, Pharm D, called the meeting to order. Stephen Calloway, RPh, facilitated the meeting on behalf of the MO HealthNet Division (MHD). Introductions were made all around.
<b>Minutes Review and Approval</b>	Minutes of the January 2018 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
<b>Pharmacy Program/Budget Update</b>	Stephen Calloway, RPh, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
<b>Old Business Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions to be implemented April 2018. Pending ratification, PDL decisions from December/January will be implemented
<b>Preferred Drug List (PDL) Annual Review</b>	
<b>Preferred Drug List (PDL)</b>	
<b>Actinic Keratosis Agents - Topical Edits</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Androgenic Agents - Topical</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> </ul>
<b>Brineura Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antibiotics - Inhaled</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Respiratory Monoclonal Antibodies (Omalizumab Edits)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antibiotics (Oral Cephalosporins Agents) - Oral</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Morphine Milligram Equivalent (MME) Accumulation Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Antihistamines – Intranasal</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antihistamines – Low Sedating (2<sup>nd</sup> Generation)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Antihistamines/Decongestants – Low-Sedating</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antihistamines – Ophthalmic</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Antiparasitics - Topical</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antivirals – Topical</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Atopic Dermatitis Agents (Topical Immunomodulators)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Benzoyl Peroxide/Antibiotic Combinations – Topical</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Beta Adrenergic Agents (Long-Acting)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>
<b>Beta Adrenergic Agents – Nebulized</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Beta Adrenergic Agents (Short Acting)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>

<b>COPD Anticholinergic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>
<b>Corticosteroids and Rhinitis Agents – Intranasal</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>
<b>Corticosteroids – Oral Inhaled</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>
<b>Corticosteroids - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cough &amp; Cold Products</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cough &amp; Cold Opioid Combination Products</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Epinephrine Self-Injectable Products</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Fluoroquinolones - Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Fluoroquinolones - Otic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Herpes Antivirals – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes).</li> </ul>

<b>Leukotriene Modifiers – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Mast Cell Stabilizers - Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>NSAIDS – Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Pancreatic Enzymes</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Prostaglandin Agonists (Glaucoma Agents)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Psoriasis Agents – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Psoriasis Agents – Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Retinoids – Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ulcerative Colitis Agents – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ulcerative Colitis Agents – Rectal</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Call Center Statistics Clinical Edit Summary Report</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to Cyber Access. Reports also detailed the number and type of prescribers and active users on Cyber Access.
<b>Conduent Update</b>	Luke Boehmer, Pharm D, presented the following items for review. The Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's. Dr. Boehmer also presented an updated analysis of the Opioid

	Edits that included the distinct members over 90 MME and also the number of opioid naïve participants that we currently have over 50 MME without a PA. Lastly, Dr. Boehmer presented the New Drug Summary,
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a>
<b>Program Utilization: Top 25 Drugs Summary</b>	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 <sup>nd</sup> , 3 <sup>rd</sup> , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Adjourn</b>	Charlene Heyde, RPH, made a motion to move to close the meeting under Section 610.021 (5), (14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned entertaining no further business, actions, or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for July 18, 2018, at the <b>Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO.</b>

### Roll Call Votes – April 18, 2018

<b>MEMBERS</b>	<b>MEETING MINUTES</b>	<b>ALL RECOMMENDATIONS BLOCK VOTE</b>	<b>CLOSED SESSION PURSUANT TO SECTION 610.021 SUBSECTION (14), (5)</b>	<b>ADJOURN EXECUTIVE SESSION</b>
Susan Abdel-Rahman, Pharm D	Y	Y	Y	Y
Charlene Heyde, RPh	Y	Y	M, Y	Y
Sandra Bollinger, Pharm D	Y	Y	Y	S, Y
Kenneth Haller, MD	A	A	A	A
Glenn Talboy, MD	Y	S, Y	Y	Y
Jennifer Passanise, FNP	Y	M, Y	S, Y	M, Y
Stacy Mangum, Pharm D	M, Y	Y	A	A

### Drug Utilization Review Board Minutes April 18, 2018

Ginger Nicol, MD, CEDS	S,Y	Y	Y	Y
Randy Beckner, Pharm D	Y	AB, Y	A	A

**M - Motion to vote**  
**S - Second to vote**  
**Y - Yes to the vote**  
**N - No to the vote**  
**A - Absent**  
**AB - Abstain vote**

Randy Beckner abstained on Corticosteroids Oral, Corticosteroids and Rhinitis Agents-Intranasal, COPD Anticholinergic Agents, Beta Adrenergic Agents-Short Acting, Beta Adrenergic Agents-Long Acting, and Herpes Antivirals-Oral.

### EXECUTIVE SESSION April 18, 2018

#### **DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair

Charlene Heyde, RPh  
 Sandra Bollinger, Pharm D  
 Randy Beckner, Pharm D  
 Stacy Mangum, Pharm D  
 Ginger Nicol, MD, CEDS  
 Glen Talboy, MD  
 Jennifer Passanise, FNP

#### **MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
 Mark Roaseau, RPh, Clinical Pharmacist  
 Elizabeth Short, Program Development Specialist  
 Angela Wilson, Manager, Band I  
 Jenna McTeer, RN, Clinical Management  
 Lisa Smith, Program Development Specialist  
 Mitch Ruth, Fiscal Unit Manager  
 Frances (Franki) Moseley, Administrative Office Support Assistant  
 Dr. Timothy Kling, MD, Assistant Medical Director

#### **DUR BOARD MEMBERS ABSENT**

#### **CONTRACTED STAFF PRESENT**

Kenneth Haller, MD

Joshua Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Richard Pope, Pharm D, Magellan

Minutes Review	There were no January minutes for the Executive Session to be approved as submitted.
Case Reviews	No Cases for Review
Adjourn	Executive session